Patents by Inventor Toshiki Ochi

Toshiki Ochi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12241061
    Abstract: Provided are a CAR library used to screen scFvs that can be functional in CAR-T cells, and an scFv manufacturing method in which the CAR library is used. A chimeric antigen receptor (CAR) library of the present invention includes nucleic acids coding for first CARs. Each of the first CARs includes a first antigen-binding domain, a first transmembrane domain, and a first intracellular signaling domain. The first antigen-binding domain includes a first single-chain antibody (scFv) to be screened for the ability to bind to a target antigen. The first scFv includes a first heavy-chain variable region and a first light-chain variable region. The first heavy-chain variable region and the first light-chain variable region meet a predetermined condition.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: March 4, 2025
    Assignee: National University Corporation Ehime University
    Inventors: Toshiki Ochi, Masaki Yasukawa, Hiroshi Fujiwara, Katsuto Takenaka
  • Publication number: 20220290128
    Abstract: Provided are a CAR library used to screen scFvs that can be functional in CAR-T cells, and an scFv manufacturing method in which the CAR library is used. A chimeric antigen receptor (CAR) library of the present invention includes nucleic acids coding for first CARs. Each of the first CARs includes a first antigen-binding domain, a first transmembrane domain, and a first intracellular signaling domain. The first antigen-binding domain includes a first single-chain antibody (scFv) to be screened for the ability to bind to a target antigen. The first scFv includes a first heavy-chain variable region and a first light-chain variable region. The first heavy-chain variable region and the first light-chain variable region meet a predetermined condition.
    Type: Application
    Filed: February 4, 2020
    Publication date: September 15, 2022
    Inventors: Toshiki OCHI, Masaki YASUKAWA, Hiroshi FUJIWARA, Katsuto TAKENAKA
  • Patent number: 10654907
    Abstract: Provided is a method for determining a TCR polypeptide chain that can form a TCR specific for a peptide of interest. Also provided are methods and compositions for producing a cell expressing a T cell receptor (TCR) specific for a peptide of interest, methods and compositions for producing a TCR chain nucleic acid and/or pair of TCR chain polypeptides and/or nucleic acids encoding a TCR, a cell population comprising the cell harboring the nucleic acids encoding a TCR obtained by said method, and a method for treating a disorder comprising administering to the subject said cell population.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: May 19, 2020
    Assignee: University Health Network
    Inventors: Naoto Hirano, Munehide Nakatsugawa, Toshiki Ochi
  • Publication number: 20160340403
    Abstract: Provided is a method for determining a TCR polypeptide chain that can form a TCR specific for a peptide of interest. Also provided are methods and compositions for producing a cell expressing a T cell receptor (TCR) specific for a peptide of interest, methods and compositions for producing a TCR chain nucleic acid and/or pair of TCR chain polypeptides and/or nucleic acids encoding a TCR, a cell population comprising the cell harboring the nucleic acids encoding a TCR obtained by said method, and a method for treating a disorder comprising administering to the subject said cell population.
    Type: Application
    Filed: January 28, 2015
    Publication date: November 24, 2016
    Inventors: NAOTO HIRANO, MUNEHIDE NAKATSUGAWA, TOSHIKI OCHI
  • Publication number: 20120009162
    Abstract: Disclosed are: polypeptides for TCR ?-chain and ?-chain which are restricted to HLA-A*0201 for Aur-A and are derived from a CTL; and nucleic acids encoding the polypeptides. The nucleic acids can impart a cytotoxic activity against a cell capable of presenting an HLA-A*0201 molecule and an Aur-A207-215 peptide thereon to a T cell, and are therefore useful for the treatment of cancer in which Aur-A is expressed.
    Type: Application
    Filed: April 2, 2010
    Publication date: January 12, 2012
    Inventors: Masaki Yasukawa, Hiroshi Fujiwara, Toshiki Ochi, Junichi Mineno, Ikunoshin Kato